Investor Overview

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases. Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has a collaboration agreement with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development.

Upcoming Events

Date Event Details
Summary Toggle Oct 11, 2019


Podium Presentation: 24-week Results of Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial)
Abstract #: 30062032
Section: Section VIII: Late Breaking Developments, Part I
Date: October 11, 2019
Time: 4:26 p.m. – 4:31 p.m. PT
Location: Moscone Center, San Francisco, CA
Speaker: Szilard Kiss, M.D., director of clinical research in the Department of Ophthalmology at Weill Cornell Medical College